Blog

Howard McLeod: Preemptive DPYD Testing Program for patients planned for a systemic Fluoropyrimidine

Photo taken from Howard McLeod/LinkedIn

May 1, 2024, 04:54

Howard McLeod: Preemptive DPYD Testing Program for patients planned for a systemic Fluoropyrimidine

Howard McLeod, Central Director, Founder and Advisor at Precision Medicine, shared on LinkedIn:

“The USA cancer community might be late to adopt Dihydropyrimidine dehydrogenase (DPYD) testing to avoid severe/fatal toxicity from commonly used chemotherapy, but the tide has finally changed. The recent Food and Drug Administration (FDA) package insert change is followed by very successful implementation at Dana-Farber Cancer Institute. With data from community centers, such as Atrium Health and St. Elizabeth Healthcare, there are no more excuses for rest of the field.”

Additional information
Source: Howard McLeod/LinkedIn

ASCO Atrium Health cancer Childhood Cancer Dana-Farber Cancer Institute dihydropyrimidine dehydrogenase DPYD testing FDA fluoropyrimidine Howard McLeod OncoDaily Oncology St. Elizabeth Healthcare

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage